Table 3.
Functional efficacious outcomes of the included studies.
| Author | Efficacy outcomes | Description, n (%) |
|---|---|---|
| Della-Torre et.al. | PaO2/FiO2 ratio; n (%) | 200–300 mm of Hg |
| Total: 4 (7) | ||
| Sarilumab: 1 (4) | ||
| Comparison: 3 (11) | ||
| P value: 0.61 | ||
| 100–200 mm of Hg | ||
| Total: 22 (39) | ||
| Sarilumab: 10 (36) | ||
| Comparison: 12 (43) | ||
| P value: 0.78 | ||
| <100 mm of Hg | ||
| Total: 30 (54) | ||
| Sarilumab: 17 (60) | ||
| Comparison: 13 (46) | ||
| P value: 0.42 | ||
| Mortality; n (%) | Sarilumab: 2 (7) | |
| Comparison: 5 (18) | ||
| P value: 0.42 | ||
| Clinical improvement; n (%) | Sarilumab: 17 (60) | |
| Comparison: 18 (64) | ||
| P value: 0.99 | ||
| Mechanical ventilation; n (%) | Sarilumab: 6 (21) | |
| Comparison: 7 (25) | ||
| P value: 0.99 | ||
| Montesarchio et.al. | PaO2/FiO2 ratio | 122 (83–240) |
| Mortality; n (%) | 5 (33.3) | |
| Intubated vs. not intubated; n (%) | 8 (53.3) vs. 7 (46.7) | |
| Benucci et.al. | PaO2/FiO2 ratio | Improvement of oxygenation expressed by an increased SpO2/FiO2 ratio (Horovitz index) by 50 or higher compared to nadir SpO2/FiO2 for at least 48 hours: seven of them showed an improvement of the Horovitz index |
| Mortality; n | 7 survived and 1 died | |
| Lescure et.al. | PaO2/FiO2 ratio | Total: 237·5 (173·6–300·0) |
| Placebo: 240·0 (190·0–332·1) | ||
| Sarilumab (200 mg): 230·0 (165·0–296·9) | ||
| Sarilumab (400 mg): 237·5 (172·7–293·8) | ||
| Mortality (seven-point scale); n (%) | Total: 9 (11%) | |
| Sarilumab (200 mg): 17 (11%) | ||
| Sarilumab (400 mg): 18 (10%) | ||
| Noninvasive ventilation; n (%) | Total: 7 (2%) | |
| Placebo: 2 (2%) | ||
| Sarilumab (200 mg): 3 (2%) | ||
| Sarilumab (400 mg): 2 (1%) | ||
| Invasive mechanical ventilation; n (%) | Total: 48 (12%) | |
| Placebo: 9 (11%) | ||
| Sarilumab (200 mg): 16 (10%) | ||
| Sarilumab (400 mg): 23 (13%) | ||
| Gremese et.al. | PaO2/FiO2 ratio | No ICU care: 167.5 (125.4–226.5) |
| ICU care: 101.0 (89.0–141.0) | ||
| P value: 0.007 | ||
| Mortality; n (%) | No ICU care: 1 (2.5%) | |
| ICU care: 2 (14.2%) |
ICU: intensive care unit.